Armata Pharmaceuticals Inc ARMP Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Patti Joseph M

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

54,343

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Patti Joseph M

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,666

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Kramer Robin

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

54,343

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Kramer Robin

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,666

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Peterson Todd C.

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

54,343

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Peterson Todd C.

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,666

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Rychlik Richard

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

40,000

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Rychlik Richard

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Schlesinger Sarah J.

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

54,343

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Schlesinger Sarah J.

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,666

Price:

--

Filings by filing date

Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Patti Joseph M

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

54,343

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Patti Joseph M

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,666

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Kramer Robin

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

54,343

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Kramer Robin

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,666

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Peterson Todd C.

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

54,343

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Peterson Todd C.

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,666

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Rychlik Richard

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

40,000

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Rychlik Richard

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Schlesinger Sarah J.

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

54,343

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Schlesinger Sarah J.

Ownership Type:

Direct Ownership

Securities:

Stock Options (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

39,666

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	5005 Mcconnell Ave LOS ANGELES CA 90066
Tel:	1-212-9152569
Website:	https://www.armatapharma.com
IR:	See website

Key People

Deborah L. Birx Chief Executive Officer, Director	Richard Rychlik Principal Financial Officer

Business Overview

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Financial Overview

For the fiscal year ended 31 December 2023, Armata Pharmaceuticals Inc revenues decreased 18% to $4.5M. Net loss increased 87% to $69M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General & Adminstrative increase of 91% to $11.7M (expense), Interest expense increase from $0K to $2.6M (expense).

Employees:	66 as of Mar 1, 2024

Reporting Currency:	U.S. Dollars
Enterprise value:	$159.52M as of Dec 31, 2023
Annual revenue (TTM):	$4.53M as of Dec 31, 2023
EBITDA (TTM):	-$39.91M as of Dec 31, 2023
Net annual income (TTM):	-$69.05M as of Dec 31, 2023
Free cash flow (TTM):	-$55.57M as of Dec 31, 2023
Net Debt Last Fiscal Year:	$68.78M as of Dec 31, 2023
Shares outstanding:	36,148,539 as of Mar 15, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization